Velico Medical

Executive Summary

Velico Medical is a private, clinical-stage medtech company developing the FrontlineODP™ System, a spray-dried plasma manufacturing platform designed to enable on-demand, point-of-care plasma production at blood centers. The company aims to reduce preventable deaths from bleeding by improving the shelf life and accessibility of specialized blood products. Currently in Phase 1 clinical development, Velico addresses a critical need in trauma care and remote settings where conventional frozen plasma is logistically challenging. The FrontlineODP technology has the potential to transform transfusion medicine by providing a portable, stable plasma product that can be rapidly reconstituted at the bedside. With its unique approach and a clear unmet need, Velico is positioned in a niche but impactful market. However, as an early-stage private company, it faces typical development and funding risks. The executive summary highlights the company's innovative solution, clinical progress, and strategic focus on improving trauma outcomes.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Clinical Trial Data Readout70% success
• Q2 2027FDA Breakthrough Device Designation or Similar60% success
• Q3 2027Strategic Partnership or Funding Round50% success